spacer
home > pmps > summer 2019 > leaving on a jet plane
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Leaving on a Jet Plane

‘Leaving on a jet plane’ is the title of one of John Denver’s greatest hits. However, it is also what an increasing number of pharmaceutical products do every day, when the results of Medicon Valley based R&D, commercialisation, and manufacturing are sent out to make a difference worldwide.

The binational Danish-Swedish life sciences cluster Medicon Valley consists of the Region Zealand, the Danish Capital Region, and the Swedish region Skåne. It is not only host to cutting-edge public and private life sciences R&D in, for instance, oncology, dermatology, diabetes, fertility, and CNS-related diseases, but also the world’s largest insulin manufacturing site owned by Novo Nordisk and located in the Danish city of Kalundborg. Additionally, Medicon Valley-based companies such as LEO Pharma, Baxter, Coloplast, Ferring, and Lundbeck have substantial local production and/or R&D facilities; this makes Copenhagen Airport a central logistics hub and, since it serves Denmark and South Sweden alike, the most important airport in the Nordics from a life sciences perspective.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Petter Hartman is the CEO of Medicon Valley Alliance since June 2015 and holds a Masters in Political Science from the University of Lund, Sweden. At Medicon Valley Alliance, Petter is involved in future strategies for the Medicon Valley region, general management within the public sector, project management, and pharma R&D. Petter comes from a post as Funding Manager at Medicon Valley Alliance. Prior to joining, Petter worked for the Secretariat for Interreg IV A Öresund-Kattegat- Skagerrak, Copenhagen, as a project consultant with special responsibility for issues concerning cross-border relations and labourmarket integration projects.
spacer
Petter Hartman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Restructure Announcement at Illingworth

As a rapidly growing company, Illingworth Research Group (Illingworth) has reflected on its goals, accomplishments and ambitious future growth plans. This has allowed us to consider opportunities for staff to explore their own growth and development possibilities within a rapidly changing landscape. With that in mind, Illingworth are announcing some significant and exciting changes to our organization. Illingworth remain committed to making patient involvement in clinical trials as stress free as possible and our strengthened management team and launch of our patient concierge service, PatientGO, in combination with global, mobile research nursing will ensure as many patients as possible have the chance to participate in the development of critical drugs, regardless of their geography or socioeconomic class.
More info >>

White Papers

Backward Thinking

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market.
More info >>

 
Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement